On 12 July 2012, internationally renowned experts in renal carcinoma, Dr. Brian Rini and Dr. Jorge García from the Cleveland…
news
Nature Medicine´s Senior Editor, Vicotria Aranda will come to VHIO Monday 17 September 2012 to deliver the 4th in the prestigious series of VHIO Meet the Editors talks.
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors.
– The study was presented at the annual meeting of ASCO (American Society of Clinical Oncology) revealing findings surrounding the largest sample of breast cancer patients treated with this group of drugs.
– This research presented at ASCO was honored through a Merit Award from the Conquer Cancer Foundation — testament to its high quality and important scientific interest.
21 May 2012, Barcelona – Héctor G. Palmer, Principal Investigator of the Stem Cells and Cancer Group at the Vall…
The Vall d’Hebron Institute of Oncology (VHIO) identifies biomarkers that predict resistance to treatment which will enable a better selection of patients who stand to benefit as well as avoid the administration of ineffective medicines.
These findings identify experimental drugs to overcome resistance and open new therapeutic avenues in combinatorial treatment.
CALL FOR APPLICATIONS 2012 The objective of the Fellowship is to provide support to two outstanding MD’s, PhD’s, or MD/PhD’s…
VHIO Meet the Editors with The New England Journal of Medicine: Monday 14 May 2012
The New England Journal of Medicine´s Bette Phimister, Deputy Editor, will join us to deliver the next in the prestigious series of VHIO Meet the Editors talks:
Publishing Advances in Cancer Research
Bette Phimister will review progress and pitfalls in cancer research and issues concerning its publication, with a focus on targeted therapies and an eye to future developments.
EACR 22 – from Basic Research to Personalised Cancer Treatment, 7 – 10 July 2012, Barcelona, Spain, is pleased to announce the following Pre-Congress Sympoium:
The Seve Ballesteros Foundation Special Conference on Brain Cancer, Saturday 7 July, 08:30 – 12:30h.
A study by the Vall d’Hebron Institute of Oncology (VHIO) demonstrates that by combining drugs which had already been used previously, but became ineffective, they boost each other’s efficacy and at the same time overcome the resistance developed by the patient to each individual drug. This strategy could offer an unprecedented key to multiplying treatment options.
